Cathepsin S regulates antitumor immunity through autophagic degradation of PD-L1 in colorectal cancer cells.
Saved in:
| Title: | Cathepsin S regulates antitumor immunity through autophagic degradation of PD-L1 in colorectal cancer cells. |
|---|---|
| Authors: | Taheri Baghmisheh S; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan., Chen CH; Department of Mathematics, University of Taipei, Taipei, Taiwan., Yeh YM; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Lin PC; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Genomic Medicine, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan., Chen PC; Division of Colorectal Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Chan RH; Division of Colorectal Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Kang JW; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Lee CT; Department of Pathology, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan., Tsai HJ; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan., Fang YC; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan., Cheung CHA; Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Chang KY; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan., Chang JY; TMU Research Center of Cancer Translational Medicine, Taipei Cancer Center, Taipei Medical University Hospital, College of Medicine, Taipei Medical University, Taipei, Taiwan.; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan., Chen SH; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. Bryanchen@nhri.edu.tw.; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Bryanchen@nhri.edu.tw. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Aug 12; Vol. 74 (9), pp. 287. Date of Electronic Publication: 2025 Aug 12. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-025-04140-x |
